Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P11021 (
BiP
)
2,049
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The transthyretin amyloidoses (ATTR) are devastating diseases characterized by progressive neuropathy and/or cardiomyopathy for which novel therapeutic strategies are needed. We have recently shown that curcumin (diferuloylmethane), the major bioactive polyphenol of turmeric, strongly suppresses
TTR
fibril formation in vitro, either by stabilization of
TTR
tetramer or by generating nonfibrillar small intermediates that are innocuous to cultured neuronal cells. In the present study, we aim to assess the effect of curcumin on
TTR
amyloidogenesis in vivo, using a well characterized mouse model for familial amyloidotic polyneuropathy (FAP). Mice were given 2% (w/w) dietary curcumin or control diet for a six week period. Curcumin supplementation resulted in micromolar steady-state levels in plasma as determined by LC/MS/MS. We show that curcumin binds selectively to the
TTR
thyroxine-binding sites of the tetramer over all the other plasma proteins. The effect on plasma
TTR
stability was determined by isoelectric focusing (IEF) and curcumin was found to significantly increase
TTR
tetramer resistance to dissociation. Most importantly, immunohistochemistry (IHC) analysis of mice tissues demonstrated that curcumin reduced
TTR
load in as much as 70% and lowered cytotoxicity associated with
TTR
aggregation by decreasing activation of death receptor Fas/CD95, endoplasmic reticulum (ER) chaperone
BiP
and 3-nitrotyrosine in tissues. Taken together, our results highlight the potential use of curcumin as a lead molecule for the prevention and treatment of
TTR
amyloidosis.
...
PMID:Dietary curcumin counteracts extracellular transthyretin deposition: insights on the mechanism of amyloid inhibition. 2306 88